UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study

European journal of cancer (1990), 2019-10, Vol.120, p.122-131

2019

Volltextzugriff (PDF)

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Journal of thoracic oncology, 2018-08, Vol.13 (8), p.1128-1137

2018

Volltextzugriff (PDF)

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-07, Vol.8 (7), p.940-946

2013

Volltextzugriff (PDF)

Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-12, Vol.138, p.109-115

2019

Volltextzugriff (PDF)

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

Clinical cancer research, 2018-11, Vol.24 (22), p.5610-5621

2018

Volltextzugriff (PDF)

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit

Scientific reports, 2023-02, Vol.13 (1), p.2007-2007, Article 2007

2023

Volltextzugriff (PDF)

Mesencephalic astrocyte-derived neurotrophic factor is secreted from interferon-γ-activated tumor cells through ER calcium depletion

PloS one, 2021-01, Vol.16 (4), p.e0250178-e0250178

2021

Volltextzugriff (PDF)

p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts

Cancer research (Chicago, Ill.), 2006-11, Vol.66 (22), p.10671-10676

2006

Volltextzugriff (PDF)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Oncoimmunology, 2021-01, Vol.10 (1), p.1865653

2021

Volltextzugriff (PDF)

Immunotherapy response modeling by ex-vivo organ culture for lung cancer

Cancer Immunology, Immunotherapy, 2021-08, Vol.70 (8), p.2223-2234

2021

Volltextzugriff (PDF)

Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes

Current oncology (Toronto), 2021-01, Vol.28 (1), p.317-331

2021

Volltextzugriff (PDF)

Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study

Cancer immunology research, 2018-12, Vol.6 (12), p.1453-1458

2018

Volltextzugriff (PDF)

Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing

Frontiers in oncology, 2022-06, Vol.12, p.912801-912801

2022

Volltextzugriff (PDF)

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy

Frontiers in immunology, 2024-02, Vol.15, p.1364473-1364473

2024

Volltextzugriff (PDF)

Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non–Small Cell Lung Carcinoma Cells

Neoplasia (New York, N.Y.), 2016-09, Vol.18 (9), p.525-535

2016

Volltextzugriff (PDF)

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease

Clinical & experimental metastasis, 2012-02, Vol.29 (2), p.123-132

2012

Volltextzugriff (PDF)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

Frontiers in oncology, 2021-03, Vol.11, p.603223-603223

2021

Volltextzugriff (PDF)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

Frontiers in oncology, 2021-07, Vol.11, p.625668-625668

2021

Volltextzugriff (PDF)

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer

Cancers, 2021-06, Vol.13 (11), p.2800

2021

Volltextzugriff (PDF)

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

Journal for immunotherapy of cancer, 2022-06, Vol.10 (6), p.e004582

2022

Volltextzugriff (PDF)

Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Clinical lung cancer, 2012-07, Vol.13 (4), p.267-279

2012

Volltextzugriff (PDF)

Involvement of stromal p53 in tumor-stroma interactions

Seminars in cell & developmental biology, 2010-02, Vol.21 (1), p.47-54

2010

Volltextzugriff (PDF)

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone

Thoracic cancer, 2022-06, Vol.13 (12), p.1763-1771

2022

Volltextzugriff (PDF)

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection

Biosensors (Basel), 2023-06, Vol.13 (6), p.627

2023

Volltextzugriff (PDF)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)

Frontiers in oncology, 2022-05, Vol.12, p.874712-874712

2022

Volltextzugriff (PDF)

1 – 25 von 186

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(163)

Publikationsform

Artikel
(185)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(103)
Life Sciences & Biomedicine
(98)
Oncology
(81)
Humans
(65)
Female
(34)
Lung Cancer
(32)
Male
(30)
Lung Neoplasms - Drug Therapy
(27)
Middle Aged
(27)
Aged
(25)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(22)
Respiratory System
(22)
Immunotherapy
(21)
Lung Neoplasms - Pathology
(16)
Lung Neoplasms - Genetics
(15)
Adult
(14)
Cancer
(14)
Carcinoma, Non-Small-Cell Lung - Genetics
(14)
Nsclc
(14)
Retrospective Studies
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non–Small-Cell Lung Cancer

Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit

Mesencephalic astrocyte-derived neurotrophic factor is secreted from interferon-γ-activated tumor cells through ER calcium depletion

p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Immunotherapy response modeling by ex-vivo organ culture for lung cancer

Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes

Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study

Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy

Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non–Small Cell Lung Carcinoma Cells

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Involvement of stromal p53 in tumor-stroma interactions

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)

Suchergebnisse filtern